39th week of 2014 patent applcation highlights part 38 |
Patent application number | Title | Published |
20140286976 | CHIMERIC HUMAN-LLAMA ANTIGENS AND METHODS OF USE - Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen. | 2014-09-25 |
20140286977 | Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties - A vaccine composition comprising a protein, which can be detected in | 2014-09-25 |
20140286978 | CYTOTOXIC T LYMPHOCYTE INDUCER - The invention provides a cytotoxic T lymphocyte inducer comprising a virus-like particle composed of VP1 of simian virus 40. The T cell epitope peptide is inserted into a DE loop and/or an HI loop of the VP1. | 2014-09-25 |
20140286979 | CANINE INFLUENZA RECOMBINANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - A canine influenza recombinant virus includes HA and NA genes of ZJCIV canine influenza virus as well as six internal genes PA, PB1, PB2, M, NP and NS of a PR8 virus. The nucleotide sequence of the HA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.1; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.1. The nucleotide sequence of the NA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.2; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.2. | 2014-09-25 |
20140286980 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length TTV genomes that can replicate efficiently in host animals and tissue culture. | 2014-09-25 |
20140286981 | BROADLY REACTIVE MOSAIC PEPTIDE FOR INFLUENZA VACCINE - The invention provides for mosaic influenza virus HA and NA sequences and uses thereof. | 2014-09-25 |
20140286982 | MULTIMERIC MULTIEPITOPE INFLUENZA VACCINES - An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X | 2014-09-25 |
20140286983 | DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES - Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. | 2014-09-25 |
20140286984 | Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 2014-09-25 |
20140286985 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 2014-09-25 |
20140286986 | POLYPEPTIDES HAVING IMMUNOACTIVATING ACTIVITY AND METHODS OF PRODUCING THE SAME - Isolated polypeptides are provided that comprise a cholera toxin B subunit variant having one or more modifications to increase the expression of the polypeptide in a plant cell. Nucleic acids sequences, vectors, and plant cells for expressing the cholera toxin B subunit variant polypeptides are also provided. Further provided are methods for producing the cholera toxin B subunit variant polypeptides that include the steps of transforming a plant cell with a nucleic acid encoding the cholera toxin B subunit variant polypeptides; expressing the variant polypeptides; and purifying the polypeptides. Still further provided are methods of isolating the variant polypeptides that include the steps of obtaining a plant cell expressing the cholera toxin B subunit variant polypeptides; extracting the cholera toxin B subunit variant polypeptides from the plant cell; and purifying the cholera toxin B subunit variant polypeptides. Methods of eliciting an immune response are also provided. | 2014-09-25 |
20140286987 | METHODS FOR CONTROLLING T CELL PROLIFERATION - The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject. | 2014-09-25 |
20140286988 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM - 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. | 2014-09-25 |
20140286989 | COMPOUND, EXTRACT ISOLATED FROM ANTRODIA CAMPHORATE, AND METHOD OF INHIBITING CANCER CELL GROWTH - Disclosed is a compound isolated from | 2014-09-25 |
20140286990 | MUD MASK WITH REAL LEAF AND METHOD FOR MAKING THE SAME - A mud mask with real leaves is described. The mud mask is made by separating a leaf batch into a first sub-batch, a second sub-batch, and a third sub-batch. The first sub-batch is ground into a fine powder, while the second sub-batch remains as whole leaves and the third sub-hatch is chopped into partially chopped leaves. The fine powder and whole leaves are added to hot water for a period of time to form a brewed tea. Thereafter, the partially chopped leaves and mud components are added to the brewed tea to form a mud solution, which is mixed to form the mud product. The mud product is packaged and allowed to marinate, which allows the leaves to begin releasing their nutrients and antioxidants into the mud formula, after which the mud mask includes atypical and unusually high levels of nutrients, antioxidants and caffeine. | 2014-09-25 |
20140286991 | COMBINED CELL BASED GP96-IG-SIV/HIV, RECOMBINANT GP120 PROTEIN VACCINATION FOR PROTECTION FROM SIV/HIV - Compositions are provided comprising heat shock protein, immunoglobulins and retroviral antigens to induce systemic and mucosal immunity to infection from retroviruses such as Human Immunodeficiency Virus (HIV). Methods of treatment provided comprise administration of the compositions, which boost the immune systems response to the retroviral antigens or immunogens. | 2014-09-25 |
20140286992 | INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONS - Influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs. | 2014-09-25 |
20140286993 | IMMUNE METHODS AGAINST INFLUENZA VIRUSES AND COMBINATORIAL VACCINES THEREOF - The invention provides a method of preventing the spreading of influenza viruses, and the factors making up the said method, and especially provides one type of combinatorial vaccine and the immunization method thereof. Two of more influenza vaccines are inoculated by a certain sequence, and each influenza vaccine vaccines is inoculated at least once, and the inoculation take place two or more times; wherein each influenza vaccine includes one or more antigens, the immunogenic fragments thereof, or the coding genes thereof, and further includes a different antigen, the immunogenic fragments or the coding gene of the different antigen. | 2014-09-25 |
20140286994 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 2014-09-25 |
20140286995 | NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 3a - A nucleic acid includes, in the following order, a 5′ untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3′ untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a. | 2014-09-25 |
20140286996 | Modified Gram-Negative Bacteria For Use As Vaccines - The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host. | 2014-09-25 |
20140286997 | ARABINOGALACTAN FOR ENHANCING THE ADAPTIVE IMMUNE RESPONSE - The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore, the present invention relates to a vaccination kit comprising a composition comprising Arabinogalactan and a vaccine. | 2014-09-25 |
20140286998 | Double-Stranded RNA For Immunostimulation - The present invention relates to a ribonucleic acid (RNA) of double-stranded structure which is capable of triggering Toll-like receptor 3 (TLR-3) and which shows an increased serum stability while simultaneously being unable to be processed by the DICER complex. | 2014-09-25 |
20140286999 | VACCINE PREPARATION CONTAINING TRIFUNCTIONAL ANTIBODIES WITH ANTIGEN IMMUNOGENICITY ENHANCER PROPERTIES - The present invention refers to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to a specific target antigen(s) for use in a method of immunizing mammals against diseases in which said target antigen(s) is (are) involved, and further to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to (a) specific target antigen (s) which is (are) involved in a disease of a mammal, specifically a human. | 2014-09-25 |
20140287000 | TUMOR PROLIFERATION INHIBITOR CONTAINING ULTRASOUND-SENSITIVE SUBSTANCE AND METHOD FOR INHIBITING TUMOR PROLIFERATION BY USING TUMOR PROLIFERATION INHIBITOR AND LOW-INTENSITY PULSED ULTRASOUND WAVES - Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. | 2014-09-25 |
20140287001 | Compositions Useful For The Treatment Of Gastrointestinal Disorders - This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy. | 2014-09-25 |
20140287002 | Agonists Of Guanylate Cyclase And Their Uses - This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents. | 2014-09-25 |
20140287004 | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs - The present invention provides methods of limiting cell death or damage or reperfusion damage resulting from hypoxic-ischemia, comprising administering an omega-3 triglyceride emulsion after a hypoxic-ischemia insult. The omega-3 triglyceride emulsion preferably comprises from about 7% to 35% omega-3 oil by weight in grams per 100 ml of emulsion; the omega-3 oil comprises about 20% to 100% triglyceride by weight per total weight of the omega-3 oil and about 20% wt.-% to 100% of the acyl-groups of the omega-3 triglycerides consist of DHA; the omega-3 oil comprises less than 10% omega-6 fatty acids; and the mean diameter of lipid droplets in the emulsion is less than about 5 microns. | 2014-09-25 |
20140287005 | PHOTOPROTECTIVE COMPOSITION CONTAINING AN UNMODIFIED GELLING STARCH AND POLYAMIDE PARTICLES - The present invention relates to a composition intended for protecting the skin and/or hair against ultraviolet radiation, characterized by the fact that it comprises, in a cosmetically acceptable support containing at least one aqueous phase, at least: (a) a photoprotective system capable of screening out UV radiation; (b) at least one gelling starch that is not modified by a chemical or physical process; and (c) polyamide particles, in particular polyamide PA-12 or polyamide PA-6 particles. The present invention also relates to the use of the combination of at least one gelling starch that is not modified by a chemical or physical process and polyamide particles in a composition comprising, in a cosmetically acceptable support comprising at least one aqueous phase, at least one photoprotective system capable of screening out UV radiation, for the purpose of improving the cosmetic properties after application, especially the non-tacky effect, non-greasy effect, non-shiny effect and/or the absence of residual film. | 2014-09-25 |
20140287006 | Degradation-Stabilised, Biocompatible Collagen Matrices - The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field. | 2014-09-25 |
20140287007 | AEROSOL SHAVE COMPOSITION COMPRISING A HYDROPHOBICAL AGENT FORMING AT LEAST ONE MICRODROPLET - An aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicone, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns. | 2014-09-25 |
20140287008 | HYBRID POLYUREA FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAME - A hybrid polyurea encapsulate formulation obtained by mixing a starch/fragrance emulsion with a polyurea capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof. | 2014-09-25 |
20140287009 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED PRODUCTS FORMED THEREOF - One form of the present invention provides a resin composition and a molded product formed thereof, wherein a polymer composition which includes a thermoplastic base polymer or base polyblend (A), a thermoplastic base polymer or base polyblend (B) having no compatibility with the (A), and fluid (C) included as a nanoparticle suspension having compatibility with neither (A) nor (B) and containing nanoparticles uniformly dispersed at a temperature lower than or equal to the thermal decomposition temperature of (A) or (B), and in which interfaces between three layers made of (A), (B), and (C) form three-dimensional continuous parallel interfaces, and the nanoparticles of (C) having an average particle size from 1 μm to 1 nm after removal of a dispersion medium of (C) by evaporation are locally unevenly dispersed in the pattern of a curve or a straight line connecting consecutive points at a fracture surface, and are macroscopically uniformly dispersed. | 2014-09-25 |
20140287010 | NANOPARTICLE FORMULATIONS OF ACTIVE INGREDIENTS - The present invention provides a composition including a polymer nanoparticle and at least one agricultural active compound incorporated with the nanoparticle, wherein the nanoparticle are less than 100 nm in diameter, and the polymer includes a polyelectrolyte. | 2014-09-25 |
20140287011 | ARTHROPOD PEST CONTROL COMPOSITION - Disclosed is an arthropod pest control composition comprising 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole and an inert carrier, wherein the volume median diameter of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole is from 1.5 to 5.9 | 2014-09-25 |
20140287012 | ANTIBACTERIALLY-ACTING MOULDED ARTICLE, METHOD FOR STERILIZING FORMULATIONS, STORAGE VESSEL, AND USE OF THE STORAGE VESSEL - The present invention relates to an antibacterially-acting moulded article which is formed from a moulding compound which comprises at least one sort of a particular antibacterial material. The invention is distinguished by the moulded article having an essentially cylindrical, cuboid, spherical or ellipsoid basic body, the basic body having special dimensions which depend upon the average particle diameter of the particular antibacterial material which is used. | 2014-09-25 |
20140287013 | Control of Parasites - The invention concerns a composition for the treatment of | 2014-09-25 |
20140287014 | HIGH DENSITY FIBROUS POLYMERS SUITABLE FOR IMPLANT - This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers. | 2014-09-25 |
20140287015 | CERAMIDASE AND CELL DIFFERENTIATION - The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells of a population in a differentiated state, producing a population of differentiated cells, and treating certain diseases or disorders. Each of these methods involves treating a cell population with, and/or culturing a cell population in, a ceramidase | 2014-09-25 |
20140287016 | IMMOBILIZATION OF AN ACTIVE AGENT ON A SUBSTRATE - The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof. | 2014-09-25 |
20140287017 | Solid Forms for Tissue Repair - This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof. | 2014-09-25 |
20140287018 | NANOPARTICLE-BASED SCAFFOLDS AND IMPLANTS, METHODS FOR MAKING THE SAME, AND APPLICATIONS THEREOF - Implant-associated bacterial infections are one of the most serious complications in orthopedic surgery. Treatment of these infections often requires multiple operations, device removal, long-term systemic antibiotics, and extended rehabilitation, and is frequently ineffective, leading to worse clinical outcomes and increased financial costs. Silver nanoparticle/poly(DL-lactic-co-glycolic acid) (PLGA)-coated stainless steel alloy (SNPSA) was evaluated as a potential antimicrobial implant material. It was found that SNPSA exhibited strong antibacterial activity in vitro and ex vivo, and promoted MC3T3-E1 pre-osteoblasts proliferation and maturation in vitro. Furthermore, SNPSA implants induced osteogenesis while suppressing bacterial survival in contaminated rat femoral canals. The results indicate that SNPSA has simultaneous antimicrobial and osteoinductive properties that make it a promising therapeutic material in orthopedic surgery. | 2014-09-25 |
20140287019 | Implantable Devices for Delivery of Bioactive Agents - An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent. | 2014-09-25 |
20140287020 | SURGICAL DEVICE FOR SKIN THERAPY OR TESTING - A device, and method of making the device, capable of therapeutic treatment and/or for in vitro testing of human skin. The device may be used on skin wounds for burned, injured, or diseased skin, and provides structures and functions as in normal uninjured skin, such as barrier function, which is a definitive property of normal skin. The device contains cultured dermal and epidermal cells on a biocompatible, biodegradable reticulated matrix. All or part of the cells may be autologous, from the recipient of the cultured skin device, which advantageously eliminates concerns of tissue compatibility. The cells may also be modified genetically to provide one or more factors to facilitate healing of the engrafted skin replacement, such as an angiogenic factor to stimulate growth of blood vessels. The inventive device is easy to handle and manipulate for surgical transplant, can be made into large sheets to minimize the number of grafts required to cover a large surface area to be treated, and can be produced within the time frame to treat a burned individual requiring a skin graft. | 2014-09-25 |
20140287021 | TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound. | 2014-09-25 |
20140287022 | LIPOSOMAL FORMULATIONS - The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise liposomes formed from dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol; and an antigenic polypeptide comprising a first polypeptide sequence, and a second polypeptide sequence heterologous the first polypeptide sequence which comprises a transmembrane sequence from a membrane protein, said transmembrane sequence having a number of residues sufficient to cross a lipid bilayer, at least nine contiguous residues of which are predicted to form an alpha helix having a hydrophobicity score of about 0.7 or greater. | 2014-09-25 |
20140287023 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES - 5′-triposphate oligoribonucleotides, pharmaceutical compositions comprising said 5′-triposphate oligoribonucleotides, and methods of using said 5′-triposphate oligoribonucleotides to treat viral infections are disclosed. | 2014-09-25 |
20140287024 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS - Disclosed are nanoparticle-based medicine/nutrient delivery system that are coated or incorporated with oxidized phospholipids as targeting ligands. Such delivery systems can specifically target macrophages, which are determinant cells in the aortic wall for atherosclerotic lesion development, to significantly increase bioavailability and specificity for the prevention, diagnosis and treatment of atherosclerosis. | 2014-09-25 |
20140287025 | Sustained Release Composition For Local Injection to Treat Eye Diseases - The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups. | 2014-09-25 |
20140287026 | PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol polyethylene glycol ether) | 2014-09-25 |
20140287027 | Vesicle-encapsulated corticosteroids for the treatment of cancer - The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid, and optionally an amphipathic vesicle-forming lipid and/or a negatively charged vesicle-forming lipid. | 2014-09-25 |
20140287028 | Use of Chemotherapeutic Agents - The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals. | 2014-09-25 |
20140287029 | IMMUNOGENIC EPITOPES OF NGEP ANTIGEN - The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof. | 2014-09-25 |
20140287030 | ANTILEISHMANIAL COMPOSITIONS AND METHODS OF USE - In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from | 2014-09-25 |
20140287031 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS - The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability. | 2014-09-25 |
20140287032 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase - The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid. | 2014-09-25 |
20140287033 | LIPID THERAPY - A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation. | 2014-09-25 |
20140287034 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 2014-09-25 |
20140287035 | PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY - Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies. | 2014-09-25 |
20140287036 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 2014-09-25 |
20140287037 | EXTENDED-RELEASE TOPIRAMATE CAPSULES - An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s). | 2014-09-25 |
20140287038 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 2014-09-25 |
20140287039 | Abiraterone Acetate Formulation - Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequestering agent as well as methods for producing and using such compositions are described. | 2014-09-25 |
20140287040 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 2014-09-25 |
20140287041 | Methylphenidate Extended Release Chewable Tablet - An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 2014-09-25 |
20140287042 | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases - The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubric ants, colorants and combinations thereof. | 2014-09-25 |
20140287043 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS - Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein. | 2014-09-25 |
20140287044 | FIBRIN SEALANT (FIBRINGLURAAS) CONSISTING OF A KIT OF LYOPHILIZED OR FROZEN HIGH CONCENTRATE FRIBINOGEN - The application is directed to a fibrin sealant (FIBRINGLURAAS®) consisting of a kit of lyophilized or frozen high concentrate fribinogen in which 5% a1at will be added into the final bulk and or 5% a1at as a diluent for high concentrate fibrinogen and new found proteins kh30, kh31, kh32, kh44, kh46, kh47, and kh52 in which the kh good healthy cells are present, either non-heated or heating to at least 1° C. and above, preferably at least 101° C., and lyophilized or frozen thrombin used to compound glue membrane, the diameter of which is less than 10 micrometers the actual size of the glue membrane of the fibrin sealant (FIBRINGLURAAS®) is from 0.6 μm, to 101° C. heating 0.005 micrometers and its topical applications for all solid tumor cancer | 2014-09-25 |
20140287045 | METHOD OF PREPARING MICROSPHERES BY USING POLYMER HAVING SOL-GEL TRANSITION PROPERTY AND MICROSPHERES PREPARED THEREBY - The present invention relates to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby, and more particularly, to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby capable of preventing a solvent in a polymer solution for a carrier from being rapidly diffused to the aqueous medium before formation of the microspheres to reduce porosity of the microspheres and reduce surface roughness of the microspheres in order to obtain microspheres having a sphere shape, and increasing an encapsulation ratio of a bioactive substance, by using a polymer having a sol-gel transition property as a surfactant included in an aqueous medium into which a primary emulsion is injected and gelating a secondary emulsion formed after injecting the primary emulsion using the sol-gel transition property of the polymer used as the surfactant. | 2014-09-25 |
20140287046 | NON-FLUORIDE CONTAINING DIETARY SUPPLEMENT TOOTHPASTE AND METHODS OF USING THE SAME - A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains more than about 2 percent of the reference daily intake (RDI) of the dietary supplement. | 2014-09-25 |
20140287047 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications. | 2014-09-25 |
20140287048 | PASTE COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUG - An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle. | 2014-09-25 |
20140287049 | NANOPARTICLE-BASED DRUG DELIVERY - Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity. | 2014-09-25 |
20140287050 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology. | 2014-09-25 |
20140287051 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS - The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention. | 2014-09-25 |
20140287052 | TREATMENT OF ADRENAL INSUFFICIENCY - The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to paediatric treatment regimens, the treatment of the elderly and non-human animals. | 2014-09-25 |
20140287053 | INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITH - Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant. | 2014-09-25 |
20140287054 | COMPOSITION COMPRISING BIOACTIVE AMINO ACIDS AND/OR PEPTIDES AND MARINE OIL IN A STABLE OIL-IN-WATER EMULSION, AND THE USE OF SAID COMPOSITION AS A FUNCTIONAL OR THERAPEUTIC COMPOSITION - The present invention relates to food supplements. Particularly, the present invention relates to a composition comprising marine oil in a stable oil-in-water emulsion, further comprising at least one specific bioactive amino acid or peptide, or derivatives thereof. In addition, the present invention relates to a process for the production of said composition and the use of said composition as a functional or therapeutic composition. | 2014-09-25 |
20140287055 | Biodegradeable Putty Compositions and Implant Devices, Methods, and Kits Relating to the Same - Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant. | 2014-09-25 |
20140287056 | USE OF WHEY PROTEIN MICELLES FOR INFANTS AT RISK OF OBESITY OR DIABETES - The invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in insulin secretion and/or plasma IGF-1 concentration in an infant at risk of developing obesity or diabetes. The invention also relates to a nutritional composition for infants comprising whey protein micelles. Further, the invention relates to a non-therapeutic use of a nutritional composition for infants, comprising whey protein micelles. | 2014-09-25 |
20140287057 | DIETARY PRODUCT INTENDED FOR THE PREVENTION OF CARDIOMETABOLIC RISK - A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate. | 2014-09-25 |
20140287058 | COMPOSITION FOR MAINTAINING BONE HEALTH AND FOR TREATING OSTEOARTHRITIS AND OSTEOARTHROSIS OF THE JOINTS - The claimed invention relates to a composition for preventing, treating and alleviating connective tissue diseases. The composition contains the following components: a plant, drone brood, quercetin, dihydroquercetin, and rutin. The plant used can be: burdock, dandelion, marsh cinquefoil, birch, St. John's wort, goldenrod, nettle, mint, liquorice, cinquefoil, tormentil, dog rose, Jacob's Ladder, valerian, maize, cucumaria, milk thistle, oat, agrimony, everlasting, ginseng, sage, chickweed, pumpkin, willow, wild strawberry, chicory, couch grass, Jerusalem artichoke, bilberry, calendula, horseradish, garlic, poplar, knotgrass, common plantain, elecampane, red buckwheat, chamomile flowers, lemon balm, galangal, cornflower, cudweed, bur marigold. The composition is used to alleviate or prevent bone diseases, treat osteoarthritis and osteoporosis, increase bone formation and bone mineral density during bone growth and optimize peak bone mass, stimulate bone regeneration during fracture healing, and reduce bone rarefaction. The composition effectively eliminates joint pain, nourishes the osteoarticular system, promotes the growth and regeneration of connective tissue and does not have side effects. | 2014-09-25 |
20140287059 | METHOD OF TREATING A BACTERIA-INDUCED GASTRIC DISORDER - The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target. | 2014-09-25 |
20140287060 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 2014-09-25 |
20140287061 | IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF - A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition. | 2014-09-25 |
20140287062 | Powder Composition for the Disinfection of Ungulates Baths - A powder composition for the disinfection of ungulates' baths is disclosed. In particular the present invention relates to the use of a powder composition as a disinfecting agent for the preparation of the baths suitable for ungulates' prophylaxis. It comprises at least one chlorinated organic compound, copper sulphate, EDTA, a natural gum and an inorganic carbonate at specific weight percentages. | 2014-09-25 |
20140287063 | DIAGNOSTIC METHODS AND KITS FOR MONITORING RESPONSE TO CHEMOTHERAPY IN OVARIAN CANCER - Provided are methods of determining a response to a chemotherapeutic agent in a subject with ovarian cancer, comprising: determining a RNA integrity value of a sample comprising ovarian cancer cell RNA from the subject after the subject has received one or more doses of the chemotherapeutic agent; wherein a low RNA integrity value and/or RNA degradation of the cancer cell RNA is indicative that the cancer is responding to the chemotherapeutic agent and/or a high RNA integrity value and/or stable RNA integrity of the ovarian cancer cell RNA is indicative that the cancer is resistant to the chemotherapeutic agent. | 2014-09-25 |
20140287064 | Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument - Fungal infections and other disease conditions of the integument can be effectively treated with compositions containing ozonizable oils, plant extract oils and antimicrobials, when used in conjunction with solutions containing sodium chlorite. The compositions are particularly useful for treatment of resistant fungal infections. | 2014-09-25 |
20140287065 | Oral Administration of Electrolyzed Water for Treatment and Prevention of PEDv in Swine, Swine Herds and Swine Confinements - Pigs infected with PEDv often die due to dehydration caused by diarrhea. Those that survive do not reach market weight as scheduled resulting in costs to the producer. The invention includes providing electrolyzed water either as treatment for infected animals or as a prophylactic against symptom severity in uninfected animals. The electrolyzed water is used as a substitute for or as a solution with regular drinking water. Duration of symptoms for infected pigs is markedly lessened; severity of symptoms is also reduced providing a much higher survival rate. Time to market is less negatively affected for surviving pigs than those untreated, and weight at scheduled time for sale is also less effected translating into positive financial results over those expected for untreated herds. | 2014-09-25 |
20140287066 | DOSING REGIMENS AND METHODS OF TREATMENT USING CARBON MONOXIDE - The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof. | 2014-09-25 |
20140287067 | ANTI-TUMOURAL EFFECTS OF CANNABINOID COMBINATIONS - The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). | 2014-09-25 |
20140287068 | BREEDING, PRODUCTION, PROCESSING AND USE OF SPECIALTY CANNABIS - The invention provides compositions and methods for the breeding, production, processing and use of specialty | 2014-09-25 |
20140287069 | Apparatus and Method for Cellular Extract Enhancement - The invention discloses a method of increasing extracts | 2014-09-25 |
20140287070 | Dirty Dog Anti-Bacterial Paw Spritz - Dirty Dog Anti-Bacterial Paw Spritz is an all-natural way to cut down on germs and bacteria found on dogs paws. It is sprayed on the dog's paws after being exposed to dirt, germs and bacteria. The main key components in Dirty Dog Anti-Bacterial Paw Spritz are ginger and lemon essential oils, which have been proven to cut down on dirt and germs. This heals to protect the dog owner, their home and their family from many illness that are otherwise spread from these germs. | 2014-09-25 |
20140287071 | VETERINARY SUPPLEMENTS - Veterinary supplements comprising one or more Nrf2-activating agents are disclosed. The veterinary supplements may further comprise omega-3 fatty acids and collagen. The veterinary supplements are effective for treating, inhibiting, reducing and/or preventing oxidative stress. | 2014-09-25 |
20140287072 | BROAD SPECTRUM NATURAL PRESERVATIVE COMPOSITION - Disclosed herein are preservative compositions comprising effective amounts of an alcohol, such as benzyl alcohol (“BA”), ethyl alcohol or phenyl ethanol, and cinnamon bark oil (“CB”), cinnamaldehyde (“CMA”), thyme oil, thymol, galangal oil, botanical extracts or combinations thereof, each of which are preferably obtained from natural sources. These preservatives have been observed to show broad spectrum anti microbial efficacy in both anionic and cationic formulations. In certain non-limiting embodiments, such compositions further comprise tetrahydrocurcuminoid (“THC”), phenyl ethanol and/or orange oil (“OR”) or rosemary oil (“RM”). | 2014-09-25 |
20140287073 | METHOD FOR THE TREATMENT OF ADDICTION TO TOBACCO - A method for the treatment of addiction to tobacco includes the stages of i) interviewing and training of a tobacco user (patient) and an accompanying person (ii) undergoing a Domiciliary Intensive Detoxification Program, including breathing and corporal exercises, directed balneotherapy, dietary measures including the intake of selected groups of foods and aloe vera gel, hygienic and oral rehabilitation measures and (iii) adhering to a maintenance program. | 2014-09-25 |
20140287074 | Extracts of deschampsia antartica with antineoplastic activity - The present invention relates to natural extracts as a source of therapeutic compounds for human use, specifically for curing and preventing cancerous and tumorous conditions. More specifically, the present invention relates to extracts, compositions or the extracts and methods to produce the extracts from | 2014-09-25 |
20140287075 | COMBINATION OF UNSAPONIFIABLE LIPIDS COMBINED WITH POLYPHENOLS AND/OR CATECHINS FOR THE PROTECTION, TREATMENT AND REPAIR OF CARTILAGE IN JOINTS OF HUMANS AND ANIMALS - The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables (ASU) and green tea. | 2014-09-25 |
20140287076 | FATTY ACID COMPOSITION AND PLANT EXTRACT AND PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF - A fatty acid composition containing linoleic acid, linolenic acid and oleic acid is provided. Also provided is a fatty acid composition containing linoleic acid, linolenic acid and oleic acid, and at least one selected from palmitinic acid, palmitoleic acid, stearic acid, arachidic acid and docosanoic acid. A plant extract and a pharmaceutical preparation are provided, wherein the pharmaceutical preparation contains an active component including at least one of the fatty acid composition, the plant extract and modified products thereof. Also provided is an application of the fatty acid composition, the plant extract and the pharmaceutical preparation in multiple fields. The pharmaceutical preparation may function to repair various wounds and traumas in skin, mucosa, lumina and muscular tissues. | 2014-09-25 |